Published • loading... • Updated
New Cure Arrives for Chronic, Lifelong Hepatitis B Infection
Study data showed 9 of 9 evaluable NA-treated participants and all 6 treatment-naive responders maintained functional cure at 15 months.
- On Thursday, AusperBio Therapeutics, Inc. announced long-term follow-up data from Study AB-10-8004 showing its investigational therapy AHB-137 maintains functional cure for up to 15 months off all treatment in chronic hepatitis B patients.
- Chronic hepatitis B affects approximately 240 million people worldwide, yet current nucleoside analogue therapies rarely achieve functional cure, forcing most patients onto lifelong treatment.
- Data presented at AASLD The Liver Meeting 2026 in Denver show functional cure was maintained in 16 of 17 NA-treated participants at 12 months and all 6 evaluable treatment-naïve participants through 15 months.
- No clinical relapse or new safety signals emerged during follow-up, prompting AusperBio Chief Executive Officer Guofeng Cheng to state: "A functional cure only matters if it lasts after treatment stops."
- Currently, the company is evaluating AHB-137 in a Phase 3 trial in China, advancing the experimental therapy with urgency to establish it as a potential backbone for finite-duration treatment.
Insights by Ground AI
21 Articles
21 Articles
The Trinity Journal+19 Reposted by 19 other sources
AusperBio Reports Sustained Functional Cure up to 15 Months Off All HBV Treatment in Treatment-Naïve and NA-Treated Patients with Chronic Hepatitis B
Long-term follow-up supports AHB-137 as a potential finite-duration therapy; data featured in two late-breaking oral presentations at AASLD The Liver Meeting® 2026
Coverage Details
Total News Sources21
Leaning Left3Leaning Right3Center14Last UpdatedBias Distribution70% Center
Bias Distribution
- 70% of the sources are Center
70% Center
15%
C 70%
15%
Factuality
To view factuality data please Upgrade to Premium
